Your browser is no longer supported. Please, upgrade your browser.
Settings
ATRA Atara Biotherapeutics, Inc. daily Stock Chart
ATRA [NASD]
Atara Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-3.99 Insider Own4.50% Shs Outstand45.13M Perf Week-1.57%
Market Cap1.84B Forward P/E- EPS next Y-4.11 Insider Trans-19.32% Shs Float38.26M Perf Month-1.09%
Income-119.50M PEG- EPS next Q-0.92 Inst Own90.50% Short Float14.18% Perf Quarter22.41%
Sales- P/S- EPS this Y-45.40% Inst Trans10.97% Short Ratio6.55 Perf Half Y178.77%
Book/sh5.80 P/B7.02 EPS next Y-10.80% ROA-51.20% Target Price46.60 Perf Year131.91%
Cash/sh3.68 P/C11.06 EPS next 5Y- ROE-57.00% 52W Range11.80 - 49.90 Perf YTD124.86%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-15.03% Beta2.52
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low259.32% ATR2.56
Employees185 Current Ratio6.20 Sales Q/Q- Oper. Margin- RSI (14)56.90 Volatility4.83% 6.90%
OptionableYes Debt/Eq0.00 EPS Q/Q-82.60% Profit Margin- Rel Volume0.27 Prev Close40.70
ShortableYes LT Debt/Eq0.00 EarningsMay 29 AMC Payout- Avg Volume827.62K Price42.40
Recom2.30 SMA208.63% SMA503.44% SMA20079.14% Volume194,331 Change4.18%
Apr-10-18Initiated JP Morgan Overweight $56
Mar-16-18Initiated Guggenheim Neutral
Mar-05-18Reiterated Jefferies Buy $30 → $46
Feb-28-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-15-18Downgrade Citigroup Neutral → Sell
Jan-03-18Upgrade Citigroup Sell → Neutral
Oct-06-17Resumed Goldman Neutral
Jun-22-17Resumed Jefferies Buy $30
Oct-24-16Resumed Jefferies Buy
Sep-15-16Downgrade Goldman Neutral → Sell
Dec-15-15Downgrade Citigroup Buy → Sell
Nov-18-15Resumed Goldman Neutral
Sep-25-15Initiated JMP Securities Mkt Perform
Sep-09-15Initiated Canaccord Genuity Buy $80
Jun-04-15Reiterated Jefferies Buy $43 → $47
Apr-16-18 10:01AM  3 Growth Stocks for Successful Investors Motley Fool
Apr-09-18 04:45PM  Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-04-18 08:20AM  Recent Analysis Shows Multi-Color, Madrigal Pharmaceuticals, SPX, AngioDynamics, Atara Biotherapeutics, and Quanex Building Products Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
04:45AM  Ilari Hyyrynen appointed as Executive Vice President of Atria Russia GlobeNewswire
Mar-27-18 03:00AM  Atria Plc's Annual Report, Corporate Governance Statement and CSR Report 2017 have been published GlobeNewswire -6.44%
Mar-22-18 04:30PM  Atara Biotherapeutics to Participate in Three Upcoming Immuno-Oncology Conferences GlobeNewswire
Mar-16-18 08:00AM  Atara Biotherapeutics to Present at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) GlobeNewswire
Mar-15-18 07:00AM  Notice to the general meeting GlobeNewswire
Mar-09-18 07:18PM  Cramer's lightning round: I screwed up on Apache and won'... CNBC Videos
06:51PM  Cramer's lightning round: I screwed up on Apache and won't stop you from selling CNBC
Mar-06-18 04:05PM  Atara Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Feb-28-18 09:30PM  Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire -9.46%
02:26PM  5 Biotech Stocks to Sell Amid the Latest Slaughter InvestorPlace
Feb-27-18 04:01PM  Atara Biotherapeutics Announces Proposed Offering of Common Stock GlobeNewswire
11:17AM  Atara Biotherapeutics reports 4Q loss Associated Press
07:00AM  Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress GlobeNewswire
Feb-26-18 10:45AM  Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock? Zacks
Feb-23-18 03:00AM  Atria Plc: Managers' transactions GlobeNewswire
Feb-21-18 04:06PM  Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018 GlobeNewswire
Feb-15-18 01:00AM  Atria had a strong year strategy brought good result GlobeNewswire
Feb-06-18 08:25AM  New Research Coverage Highlights Atara Biotherapeutics, SPX, Entellus Medical, Columbus McKinnon, NantKwest, and Merrimack Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire +8.90%
Jan-31-18 09:46AM  5 Best-Performing Stocks of the Top ETF of January Zacks -6.09%
Jan-28-18 03:28PM  3 Biotech Stocks With Jaw-Dropping Growth Potential Motley Fool
Jan-19-18 04:00AM  Proposals of Atria Plc's nomination board for the annual general meeting GlobeNewswire +7.27%
Jan-17-18 06:10AM  Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18) TheStreet.com
Jan-16-18 07:36PM  Winners & losers from JP Morgan Healthcare Conference CNBC Videos
06:59PM  Cramer reveals the biggest winners and losers from the JP... CNBC Videos
07:19AM  Zacks.com highlights: Arbor Realty Trust, Simpson Manufacturing and Atara Biotherapeutics Zacks
Jan-15-18 08:53AM  3 Stocks in Focus on New Analyst Coverage Zacks
Jan-12-18 03:00AM  Atara Biotherapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 Investor's Business Daily +27.54%
Jan-10-18 08:00AM  Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis GlobeNewswire +6.98%
Jan-04-18 04:15PM  Atara Biotherapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire -6.49%
Jan-03-18 10:55PM  Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire +6.35%
Jan-02-18 04:01PM  Atara Biotherapeutics Announces Proposed Offering of Common Stock GlobeNewswire
08:00AM  Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) GlobeNewswire
Dec-29-17 04:33PM  Why SandRidge Energy, Atara Biotherapeutics, and Hovnanian Enterprises Jumped Today Motley Fool +18.69%
03:28PM  Why Atara Biotherapeutics Stock Is Bolting Higher Today Motley Fool
11:35AM  Atara Biotherapeutics Wins FDA Clearance for Late-Stage Trials 24/7 Wall St.
06:00AM  Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) GlobeNewswire
Dec-28-17 06:30PM  Atara Biotherapeutics to Host Corporate Update Conference Call on Friday, December 29, 2017, at 8:00 a.m. EST GlobeNewswire
Dec-27-17 01:24PM  [$$] Celgene: Two Small-Cap Biotech Stocks It's Selling Barrons.com
Dec-18-17 02:21PM  [$$] Morgan Stanley: Three Stocks It's Buying Now Barrons.com
Dec-11-17 10:00AM  Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus (EBV) Associated Post-Transplant Lymphoproliferative Disorder (PTLD) GlobeNewswire
Nov-09-17 09:02AM  Atara Biotherapeutics reports 3Q loss Associated Press -8.01%
08:00AM  Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Nov-07-17 08:00AM  Atara Biotherapeutics to Participate in Four Upcoming Investor Conferences GlobeNewswire -6.50%
Nov-02-17 11:12AM  What Is Atara Biotherapeutics Incs (ATRA) Share Price Doing? Simply Wall St.
Nov-01-17 09:00AM  Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers GlobeNewswire
Oct-26-17 08:00AM  Atara Biotherapeutics Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of Congenital Cytomegalovirus (CMV) Infection GlobeNewswire
Oct-25-17 08:00AM  Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190 GlobeNewswire -5.33%
Oct-19-17 08:00AM  Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS) GlobeNewswire
Oct-16-17 08:00AM  Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis (MS) GlobeNewswire
Sep-16-17 06:13PM  Should You Buy Atara Biotherapeutics Inc (ATRA) Now? Simply Wall St.
Sep-11-17 08:00AM  Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129 GlobeNewswire
Sep-05-17 08:00AM  Atara Biotherapeutics Receives FDA Orphan Drug Designation for ATA230 GlobeNewswire
Aug-31-17 04:15PM  Atara Biotherapeutics to Participate in Three Upcoming Investor Conferences GlobeNewswire +7.14%
Aug-25-17 07:50AM  Featured Company News Can-Fite Receives Second Milestone Payment From CKD Pharmaceuticals for Namodenoson (CF102) in South Korea ACCESSWIRE
Aug-22-17 04:35PM  Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:00AM  Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer GlobeNewswire
Aug-07-17 11:37PM  Atara Biotherapeutics reports 2Q loss Associated Press
06:36PM  Atara Biotherapeutics reports 2Q loss Associated Press
04:05PM  Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Aug-02-17 08:00AM  Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference GlobeNewswire
Jul-31-17 08:10AM  Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis (MS) GlobeNewswire
May-24-17 08:00AM  Atara Biotherapeutics to Present at Three Upcoming Investor Conferences GlobeNewswire -5.54%
May-10-17 05:00PM  Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:00AM  Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team GlobeNewswire
May-05-17 05:02AM  Atara Biotherapeutics reports 1Q loss Associated Press -6.27%
May-04-17 04:15PM  Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Apr-21-17 09:34AM  Biotech Movers: XBiotech, Atara, Bellicum TheStreet.com -10.58%
08:00AM  Atara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with ATA129 in Nasopharyngeal Carcinoma (NPC) GlobeNewswire
Apr-20-17 05:16PM  Atara Biotherapeutics shares rise on MS drug study results MarketWatch
04:20PM  Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017 GlobeNewswire
Apr-03-17 08:00AM  Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer GlobeNewswire
Mar-27-17 05:08PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
Mar-17-17 12:45PM  Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS) GlobeNewswire +7.51%
Mar-14-17 01:04PM  ATARA BIOTHERAPEUTICS, INC. Financials -11.01%
Mar-09-17 08:34AM  Atara Biotherapeutics reports 4Q loss Associated Press +8.38%
08:16AM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:00AM  Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights GlobeNewswire
Feb-10-17 04:13PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -6.52%
Feb-07-17 10:26AM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Jan-04-17 08:00AM  Atara Bio to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-17 08:00AM  Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of E GlobeNewswire +6.16%
Dec-15-16 02:01PM  Favorite Healthcare Stocks of Billionaire Seth Klarmans Baupost Group Insider Monkey
02:01PM  Favorite Healthcare Stocks of Billionaire Seth Klarmans Baupost Group at Insider Monkey
Dec-14-16 06:15AM  Atara Biotherapeutics Inc (ATRA): Are Hedge Funds Right About This Stock? Insider Monkey -13.02%
06:15AM  Atara Biotherapeutics Inc (ATRA): Are Hedge Funds Right About This Stock? at Insider Monkey
Dec-12-16 08:00AM  Atara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, to Support Potential Approval in Two Se GlobeNewswire
Dec-03-16 10:30AM  Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016 GlobeNewswire
Nov-28-16 02:21PM  Atara Biotherapeutics, Inc. :ATRA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
Nov-04-16 08:28AM  Atara Biotherapeutics reports 3Q loss +6.32%
08:16AM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:00AM  Atara Bio Announces Third Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Nov-03-16 09:00AM  Atara Bio's Collaborating Investigators to Present Results from Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016 GlobeNewswire
Nov-02-16 09:08AM  Atara Biotherapeutics (ATRA): Moving Average Crossover Alert
Oct-27-16 09:53AM  What Falling Estimates & Price Mean for Atara Biotherapeutics (ATRA)
Oct-18-16 08:00AM  Atara Bio Granted Access to Priority Medicines (PRIME) Regulatory Support for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL) for Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) GlobeNewswire
Oct-11-16 08:00AM  Atara Bio Receives Positive Opinion from EMA on Orphan Drug Designation for Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) for Treatment of CMV Infection in Patients with Impaired Immune Systems GlobeNewswire
Sep-29-16 06:00AM  'Mad Money' Lightning Round: Buy Red-Hot Suncoke Energy -5.27%
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. It is also developing ATA188 and autologous ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product to treat Wilms tumor 1; and ATA230, which is Phase II clinical trials for refractory cytomegalovirus. In addition, the company is developing ATA368 that is under preclinical development for HIV and cancers. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; and license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute. The company was founded in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ciechanover Isaac E.Chief Executive OfficerApr 12Sale42.924,400188,844197,678Apr 12 06:14 PM
Ciechanover Isaac E.Chief Executive OfficerApr 11Sale40.824,400179,628202,078Apr 12 06:14 PM
Clark Mitchall G.EVP & Chief R & QA OfficerMar 29Sale40.0722,400897,568133,671Apr 03 04:14 PM
Clark Mitchall G.EVP & Chief R & QA OfficerMar 27Option Exercise21.8572,7541,589,393256,274Mar 28 08:10 PM
Ciechanover Isaac E.Chief Executive OfficerMar 27Sale38.402007,680206,478Mar 27 08:30 PM
Ciechanover Isaac E.Chief Executive OfficerMar 27Sale37.014,200155,421206,678Mar 27 08:30 PM
Clark Mitchall G.EVP & Chief R & QA OfficerMar 27Sale37.87100,2033,795,062156,071Mar 28 08:10 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfMar 26Sale39.7918,327729,265332,905Mar 27 04:16 PM
Ciechanover Isaac E.Chief Executive OfficerMar 26Sale40.104,400176,448210,878Mar 27 08:30 PM
MCGRATH JOHNEVP & Chief Financial OfficerMar 20Sale38.833,000116,49088,762Mar 20 06:30 PM
MCGRATH JOHNEVP & Chief Financial OfficerMar 19Sale41.993,000125,97091,762Mar 20 06:30 PM
Ciechanover Isaac E.Chief Executive OfficerMar 16Sale42.004,400184,792215,278Mar 19 04:36 PM
Ciechanover Isaac E.Chief Executive OfficerMar 15Sale42.264,400185,956219,678Mar 19 04:36 PM
Ciechanover Isaac E.Chief Executive OfficerMar 12Sale46.311,00046,314224,078Mar 14 05:23 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 22Sale43.884,600201,832225,078Feb 22 07:42 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 21Sale44.214,500198,965229,678Feb 22 07:42 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 20Sale45.288,700393,936234,178Feb 22 07:42 PM
Gallagher Carol GiltnerDirectorFeb 16Sale46.501,18355,010110,920Feb 20 08:25 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 16Sale46.9710,000469,670242,878Feb 20 08:22 PM
MCGRATH JOHNEVP & Chief Financial OfficerFeb 16Sale47.376,500307,92094,762Feb 20 08:22 PM
MCGRATH JOHNEVP & Chief Financial OfficerFeb 15Option Exercise0.005,1320104,188Feb 20 08:22 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 15Option Exercise0.003,9380812,613Feb 20 08:22 PM
Fust Matthew KDirectorFeb 15Option Exercise0.001,603032,106Feb 20 08:25 PM
Gallagher Carol GiltnerDirectorFeb 15Option Exercise0.002,3650112,103Feb 20 08:25 PM
Clark Mitchall G.EVP & Chief R & QA OfficerFeb 15Option Exercise0.007,2110187,124Feb 20 08:23 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfFeb 15Option Exercise0.005530351,232Feb 20 08:24 PM
Soffer GadEVP & Chief Strategy OfficerFeb 15Option Exercise0.002,7640268,344Feb 20 08:23 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 15Sale46.8810,000468,789252,878Feb 20 08:22 PM
MCGRATH JOHNEVP & Chief Financial OfficerFeb 15Sale46.776,500304,00599,056Feb 20 08:22 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 14Sale48.5010,000484,956262,878Feb 14 07:54 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 13Sale45.1010,000451,000272,878Feb 14 07:54 PM
Turner Heather DFormer EVP, GC & Sec.Feb 09Sale38.0112,214464,21069,494Feb 12 09:00 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 09Sale37.724,400165,969282,878Feb 12 05:09 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 08Sale37.154,400163,460287,278Feb 12 05:09 PM
Ciechanover Isaac E.Chief Executive OfficerJan 26Sale36.519,300339,558291,678Jan 29 07:39 PM
Ciechanover Isaac E.Chief Executive OfficerJan 25Sale34.1010,000340,976300,978Jan 29 07:39 PM
Ciechanover Isaac E.Chief Executive OfficerJan 24Sale33.8214,400486,938310,978Jan 24 07:44 PM
Ciechanover Isaac E.Chief Executive OfficerJan 23Sale35.6724,100859,606325,378Jan 24 07:44 PM
Ciechanover Isaac E.Chief Executive OfficerJan 22Sale33.0710,000330,735349,478Jan 24 07:44 PM
Ciechanover Isaac E.Chief Executive OfficerJan 16Sale30.3860018,228359,478Jan 18 05:23 PM
MCGRATH JOHNEVP & Chief Financial OfficerJan 12Option Exercise11.0030,000330,000123,154Jan 12 07:56 PM
MCGRATH JOHNEVP & Chief Financial OfficerJan 12Sale24.7233,500828,12089,654Jan 12 07:56 PM
Ciechanover Isaac E.Chief Executive OfficerJan 12Sale30.051003,005360,078Jan 12 07:55 PM
MCGRATH JOHNEVP & Chief Financial OfficerJan 11Sale20.773,50072,69593,154Jan 12 07:56 PM
Ciechanover Isaac E.Chief Executive OfficerJan 11Sale21.9520,000438,900360,178Jan 12 07:55 PM
Ciechanover Isaac E.Chief Executive OfficerJan 10Sale19.998,600171,938380,178Jan 12 07:55 PM
MCGRATH JOHNEVP & Chief Financial OfficerDec 29Sale20.0032,000640,00096,654Jan 02 07:14 PM
Ciechanover Isaac E.Chief Executive OfficerDec 29Sale18.6320,000372,628388,778Jan 02 07:12 PM
Ciechanover Isaac E.Chief Executive OfficerDec 28Sale15.152,20033,330408,778Jan 02 07:12 PM
Ciechanover Isaac E.Chief Executive OfficerDec 13Sale14.732,20032,406410,978Dec 14 05:34 PM
Ciechanover Isaac E.Chief Executive OfficerDec 12Sale14.562,20032,032413,178Dec 14 05:34 PM
Ciechanover Isaac E.Chief Executive OfficerNov 30Sale14.402,20031,680415,378Dec 01 04:37 PM
Ciechanover Isaac E.Chief Executive OfficerNov 29Sale14.092,20030,998417,578Dec 01 04:37 PM
Soffer GadEVP & Chief Strategy OfficerNov 17Sale15.007,000105,000256,236Nov 17 06:49 PM
Clark Mitchall G.EVP & Chief R & QA OfficerNov 16Sale14.203,29046,718163,052Nov 17 06:26 PM
Gallagher Carol GiltnerDirectorNov 16Sale14.201,18416,813109,738Nov 17 06:24 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfNov 15Option Exercise0.008290344,134Nov 17 06:27 PM
Clark Mitchall G.EVP & Chief R & QA OfficerNov 15Option Exercise0.007,2120166,342Nov 17 06:26 PM
Ciechanover Isaac E.Chief Executive OfficerNov 15Option Exercise0.005,9080743,675Nov 17 06:26 PM
MCGRATH JOHNEVP & Chief Financial OfficerNov 15Option Exercise0.007,6970128,654Nov 17 06:24 PM
Fust Matthew KDirectorNov 15Option Exercise0.001,602030,503Nov 17 06:25 PM
Gallagher Carol GiltnerDirectorNov 15Option Exercise0.002,3660110,922Nov 17 06:24 PM
Soffer GadEVP & Chief Strategy OfficerNov 15Option Exercise0.004,1460263,236Nov 17 06:49 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfNov 15Sale13.361,60421,429342,530Nov 17 06:27 PM
Ciechanover Isaac E.Chief Executive OfficerNov 14Sale13.412,20029,502419,778Nov 14 08:31 PM
Ciechanover Isaac E.Chief Executive OfficerNov 13Sale13.532,20029,766421,978Nov 14 08:31 PM
Ciechanover Isaac E.Chief Executive OfficerOct 27Sale13.602,20029,920424,178Oct 30 04:17 PM
Ciechanover Isaac E.Chief Executive OfficerOct 26Sale13.572,20029,854426,378Oct 30 04:17 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfOct 16Sale14.356,00086,100343,305Oct 17 04:46 PM
Ciechanover Isaac E.Chief Executive OfficerOct 12Sale14.782,20032,516428,578Oct 12 07:55 PM
Ciechanover Isaac E.Chief Executive OfficerOct 11Sale15.252,20033,550430,778Oct 12 07:55 PM
Ciechanover Isaac E.Chief Executive OfficerSep 20Sale15.562,20034,232432,978Sep 21 04:05 PM
Ciechanover Isaac E.Chief Executive OfficerSep 19Sale15.512,20034,122435,178Sep 21 04:05 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfSep 15Sale15.306,00091,800349,305Sep 18 05:46 PM
Ciechanover Isaac E.Chief Executive OfficerSep 07Sale14.982,20032,956437,378Sep 08 04:02 PM
Ciechanover Isaac E.Chief Executive OfficerSep 06Sale15.052,20033,110439,578Sep 08 04:02 PM
Ciechanover Isaac E.Chief Executive OfficerAug 23Sale13.512,20029,722441,778Aug 24 05:10 PM
Ciechanover Isaac E.Chief Executive OfficerAug 22Sale13.562,20029,832443,978Aug 24 05:10 PM
Gallagher Carol GiltnerDirectorAug 16Sale14.301,18416,931108,556Aug 17 05:38 PM
Soffer GadEVP & Chief Strategy OfficerAug 16Sale14.532,46435,802259,090Aug 17 05:37 PM
MCGRATH JOHNEVP & Chief Financial OfficerAug 16Sale14.392,10030,219120,957Aug 17 05:36 PM
Clark Mitchall G.EVP & Chief R & QA OfficerAug 16Sale14.333,02143,291159,130Aug 17 05:34 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfAug 15Option Exercise0.008290362,909Aug 17 05:35 PM
Clark Mitchall G.EVP & Chief R & QA OfficerAug 15Option Exercise0.007,2110162,151Aug 17 05:34 PM
Ciechanover Isaac E.Chief Executive OfficerAug 15Option Exercise0.005,9080737,767Aug 17 05:34 PM
Fust Matthew KDirectorAug 15Option Exercise0.001,603028,901Aug 17 05:41 PM
Gallagher Carol GiltnerDirectorAug 15Option Exercise0.002,3660109,740Aug 17 05:38 PM
MCGRATH JOHNEVP & Chief Financial OfficerAug 15Option Exercise0.007,6970125,157Aug 17 05:36 PM
Soffer GadEVP & Chief Strategy OfficerAug 15Option Exercise0.004,1450261,554Aug 17 05:37 PM
MCGRATH JOHNEVP & Chief Financial OfficerAug 15Sale14.232,10029,883123,057Aug 17 05:36 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfAug 15Sale14.757,604112,159355,305Aug 17 05:35 PM
Soffer GadEVP & Chief Strategy OfficerAug 15Sale15.007,000105,000257,409Aug 17 05:37 PM
Ciechanover Isaac E.Chief Executive OfficerAug 11Sale14.582,20032,076446,178Aug 14 07:23 PM
Ciechanover Isaac E.Chief Executive OfficerAug 10Sale14.752,20032,450448,378Aug 14 07:23 PM
Ciechanover Isaac E.Chief Executive OfficerJul 25Sale16.032,70043,283450,578Jul 26 04:52 PM
Ciechanover Isaac E.Chief Executive OfficerJul 24Sale16.942,80047,421453,278Jul 26 04:52 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfJul 17Sale14.926,00089,520362,080Jul 18 04:24 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfJun 15Sale12.656,00075,900368,080Jun 16 04:47 PM
Gallagher Carol GiltnerDirectorJun 09Sale13.151,00013,150107,374Jun 12 05:29 PM
Ciechanover Isaac E.Chief Executive OfficerMay 31Sale13.263,45045,747456,078May 31 07:44 PM